Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Mol Carcinog ; 53(6): 488-97, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23852815

RESUMEN

Glucocorticoids (GCs) are very effective at preventing carcinogen- and tumor promoter-induced skin inflammation, hyperplasia, and mouse skin tumor formation. The effects of GCs are mediated by a well-known transcription factor, the glucocorticoid receptor (GR). GR acts via two different mechanisms: transcriptional regulation that requires DNA-binding (transactivation) and DNA binding-independent protein-protein interactions between GR and other transcription factors, such as nuclear factor kappa B (NF-κB) or activator protein 1 (AP-1; transrepression). We hypothesize that the transrepression activities of the GR are sufficient to suppress skin tumor promotion. We obtained two GCs (RU24858 and RU24782) that have dissociated downstream effects and induce only transrepression activities of the GR in a number of systems. These compounds bind the GR with high affinity and repress AP-1 and NF-κB activities while showing a lack of GR transactivation. RU24858, RU24782, or control full GCs desoximetasone (DES) and fluocinolone acetonide (FA) were applied to the dorsal skin of SENCAR mice prior to application of the tumor promoter 12-O-tetradecanoylphorbol-13-acetate (TPA), two times per week for 2 weeks. DES, FA and RU24858 reversed TPA-induced epidermal hyperplasia and proliferation, while RU24782 treatment had no effect on these markers of skin tumor promotion. All tested compounds decreased TPA-induced c-jun mRNA levels in skin. DES, FA, and RU24858, but not RU24782, were also able to reverse TPA-induced increases in the mRNA levels of COX-2 and iNOS. These findings show that RU24858 but not RU24782 reduced TPA-induced epidermal hyperplasia, proliferation, and inflammation, while both compounds reversed c-jun mRNA increases in the skin.


Asunto(s)
Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Neoplásica/metabolismo , Desoximetasona/análogos & derivados , Glucocorticoides/farmacología , Neoplasias Cutáneas/metabolismo , Animales , Animales no Consanguíneos , Anticarcinógenos/química , Anticarcinógenos/farmacología , Biomarcadores , Proliferación Celular/efectos de los fármacos , Ciclooxigenasa 2/genética , Desoximetasona/química , Desoximetasona/farmacología , Epidermis/efectos de los fármacos , Epidermis/patología , Femenino , Regulación de la Expresión Génica/efectos de los fármacos , Glucocorticoides/química , Hiperplasia , Interleucina-6/genética , Ratones , Óxido Nítrico Sintasa de Tipo II/genética , Proteínas Proto-Oncogénicas c-jun/genética , ARN Mensajero , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/genética , Acetato de Tetradecanoilforbol/efectos adversos
2.
Mol Carcinog ; 52(6): 488-96, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-22351517

RESUMEN

Activated glucocorticoid receptor (GR) acts via two different mechanisms: transcriptional regulation that requires DNA-binding, and protein-protein interaction between GR and other transcription factors, such as nuclear factor kappa B (NF-κB) or activator protein 1 (AP-1). It has been postulated that many important effects of glucocorticoids, including their anti-inflammatory properties, depend on GR's transrepressive effects on NF-κB and AP-1. In the present study, we have employed a TPA-induced model of skin inflammation and epidermal hyperplasia to determine whether partial activation of the glucocorticoid receptor by compound A (CpdA) is sufficient to reverse the effect of TPA treatment. CpdA is a nonsteroidal GR modulator with high binding affinity, is capable of partial activation of GR. Topical application of TPA twice per week for 2 wk results in inflammation and epidermal hyperplasia. TPA treatment also elevates levels of c-jun (AP-1 component), cyclooxygenase-2 (COX-2), p50 (NF-κB component), interleukin-6 (IL-6), and tumor necrosis factor (TNF) in the skin. Fluocinolone acetonide (FA) (a full GR agonist) was able to completely reverse the above effects of TPA. When applied alone, CpdA increased the epidermal thickness and keratinocyte proliferation as well as levels of c-jun, COX-2, IL-6, and IFN-γ. However, CpdA treatment resulted in a decrease in the number of p50 positive cells induced by TPA, suggesting its role in inhibition of NF-κB. The level of metallothionein-1 mRNA, regulated by GR was also significantly decreased in skin samples treated with CpdA. Our results suggest that CpdA is able to inhibit GR transactivation and activate only some transrepression properties of GR.


Asunto(s)
Acetatos/uso terapéutico , Erupciones por Medicamentos/tratamiento farmacológico , Erupciones por Medicamentos/patología , Receptores de Glucocorticoides/inmunología , Piel/efectos de los fármacos , Piel/patología , Acetato de Tetradecanoilforbol , Tiramina/análogos & derivados , Acetatos/farmacología , Animales , Ciclooxigenasa 2/análisis , Ciclooxigenasa 2/genética , Citocinas/análisis , Citocinas/inmunología , Erupciones por Medicamentos/genética , Erupciones por Medicamentos/inmunología , Epidermis/efectos de los fármacos , Epidermis/inmunología , Epidermis/metabolismo , Epidermis/patología , Femenino , Hiperplasia/inducido químicamente , Hiperplasia/tratamiento farmacológico , Hiperplasia/genética , Hiperplasia/patología , Ratones , Ratones Endogámicos SENCAR , FN-kappa B/análisis , FN-kappa B/genética , Proteínas Proto-Oncogénicas c-jun/análisis , Proteínas Proto-Oncogénicas c-jun/genética , ARN Mensajero/genética , Receptores de Glucocorticoides/agonistas , Receptores de Glucocorticoides/genética , Piel/inmunología , Piel/metabolismo , Activación Transcripcional/efectos de los fármacos , Tiramina/farmacología , Tiramina/uso terapéutico
3.
Nutr Cancer ; 63(1): 28-38, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21108125

RESUMEN

Overexposure of the skin to carcinogenic insults causes a variety of adverse effects, among them the development of skin carcinomas. Since there is a need to develop efficient chemopreventive agents based on nutrition, our goal was to determine antioxidant and anti-carcinogenic properties of grapes by evaluating grape powder developed by the California Table Grape Commission. In order to elucidate the mechanism(s) of action of grape powder, three of the major antioxidant components found in grapes-resveratrol, catechin, quercetin, and grape seed extract, containing a proanthocyanidin B-2-gallate-were evaluated for their abilities to inhibit oxidative stress and to protect the immune system. Tested antioxidants given topically and/or systemically strongly inhibited 7,12-dimethylbenz[a]anthracene (DMBA)-induced epidermal hyperplasia, proliferation, and inflammation. The hydroxylation of 2'-deoxyguanosine was markedly inhibited by topical and dietary administration of test variables, i.e., by approximately 40-70%. Simultaneous dietary and topical treatment with antioxidants reduced these biomarkers, showing strong additive and in some combinations synergistic effects. DMBA-mediated Ha-ras mutations in codon 61 were reduced by up to 50% with topical applications, but much higher inhibition was observed in mice treated with different combinations. The results of the present study clearly show impressive effects of combined topical and dietary treatments with above grape-derived antioxidants.


Asunto(s)
Antioxidantes/uso terapéutico , Neoplasias Cutáneas/prevención & control , Vitis , 8-Hidroxi-2'-Desoxicoguanosina , Animales , Peso Corporal , Ciclooxigenasa 2/análisis , Desoxiguanosina/análogos & derivados , Desoxiguanosina/análisis , Ingestión de Alimentos , Liofilización , Genes ras , Ratones , Mutación , Polvos , Neoplasias Cutáneas/patología
4.
Carcinogenesis ; 30(6): 1008-15, 2009 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-19329757

RESUMEN

The purpose of our study was to investigate in vitro the potential cancer preventive properties of several phytochemicals, i.e. grape seed extract (GSE), resveratrol (RES), ursolic acid (URA), ellagic acid (ELA), lycopene and N-acetyl-L-cysteine (NAC) to define the mechanisms by which these compounds may inhibit murine skin carcinogenesis. We measured quenching of peroxyl, superoxide and hydroxyl radicals by these phytochemicals. We also used adenosine triphosphate (ATP) bioluminescence, Caspase-Glo 3/7 and P450-Glo (CYP1A1 and CYP1B1) assays to study antiproliferative, proapoptotic and CYP-inhibiting effects of the phytochemicals. We next determined their effects on a 4 week inflammatory hyperplasia assay using 7,12-dimethylbenz[a]anthracene-induced murine skin carcinogenesis model to further understand their mechanism of action. Three murine keratinocyte cell lines, i.e. non-tumorigenic (3PC), papilloma-derived (MT1/2) and squamous cell carcinoma-derived (Ca3/7) cell lines, were used in in vitro assays. We have found that GSE, ELA and RES are potent scavengers of peroxyl and superoxide radicals. Statistically significant effects on activities of caspase-3 and -7 were observed only after GSE and URA treatments. All tested compounds protected cells from hydrogen peroxide-induced DNA damage. Using a short-term complete carcinogenesis assay, we have found that all selected compounds caused marked decreases of epidermal thickness and (except RES) reduced percentages of mice with mutation in codon 61 of Ha-ras oncogene. In conclusion, differential effects of tested phytochemicals on events and processes critical for the growth inhibition of keratinocytes in vitro and in vivo indicate that combinations of tested compounds may, in the future, better counteract both tumor initiation and tumor promotion/progression.


Asunto(s)
Anticarcinógenos/farmacología , Antineoplásicos Fitogénicos/farmacología , Depuradores de Radicales Libres/farmacología , Queratinocitos/efectos de los fármacos , Extractos Vegetales/farmacología , Neoplasias Cutáneas/prevención & control , Acetilcisteína/farmacología , Acetilcisteína/uso terapéutico , Animales , Anticarcinógenos/uso terapéutico , Antineoplásicos Fitogénicos/uso terapéutico , Hidrocarburo de Aril Hidroxilasas/metabolismo , Carotenoides/farmacología , Carotenoides/uso terapéutico , Línea Celular , Línea Celular Tumoral , Transformación Celular Neoplásica/efectos de los fármacos , Transformación Celular Neoplásica/metabolismo , Transformación Celular Neoplásica/patología , Citocromo P-450 CYP1A1/metabolismo , Citocromo P-450 CYP1B1 , Ácido Elágico/farmacología , Ácido Elágico/uso terapéutico , Femenino , Depuradores de Radicales Libres/uso terapéutico , Radicales Libres/metabolismo , Genes ras , Queratinocitos/metabolismo , Licopeno , Ratones , Mutación , Extractos Vegetales/uso terapéutico , Proteínas Proto-Oncogénicas p21(ras)/genética , Resveratrol , Neoplasias Cutáneas/metabolismo , Estilbenos/farmacología , Estilbenos/uso terapéutico , Triterpenos/farmacología , Triterpenos/uso terapéutico , Vitis/química , Ácido Ursólico
5.
Int J Oncol ; 43(3): 911-8, 2013 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-23835587

RESUMEN

The purpose of our study was to determine the effect of the combined action of phytochemicals on the early stages of skin tumorigenesis, i.e. initiation and promotion. We tested calcium D-glucarate (CG) given in the diet, while resveratrol (RES) and ursolic acid (UA) were applied topically. The 7,12-dimethylbenz[a]anthracene (DMBA)-initiated, 12-O-tetradecanoylphorbol-13-acetate (TPA)-promoted multistage skin carcinogenesis model in SENCAR mice was used. Mice received one topical dose of DMBA, then after one month, two weekly doses of TPA for 14 weeks until sacrifice. RES or UA were applied 20 min prior to DMBA or TPA treatment and 2% dietary CG was given from 2 weeks prior to 2 weeks after the DMBA dose or continually beginning 2 weeks prior to the first dose of TPA. UA applied alone and in combination with CG during the promotion stage was the only inhibitor of tumor multiplicity and tumor incidence. A number of combinations reduced epidermal proliferation, but only UA and the combination UA+CG applied during promotion significantly reduced epidermal hyperplasia. DMBA/TPA application resulted in significant increases in c-jun and p50, which were reversed by a number of different treatments. DMBA/TPA treatment also strongly increased mRNA levels of inflammation markers COX-2 and IL-6. All anti-promotion treatments caused a marked decrease in COX-2 and IL-6 expression compared to the DMBA/TPA control. These results show that UA is a potent inhibitor of skin tumor promotion and inflammatory signaling and it may be useful in the prevention of skin cancer and other epithelial cancers in humans.


Asunto(s)
Carcinogénesis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Fitoquímicos/administración & dosificación , Neoplasias Cutáneas/genética , 9,10-Dimetil-1,2-benzantraceno/toxicidad , Animales , Carcinogénesis/inducido químicamente , Ciclooxigenasa 2/biosíntesis , Femenino , Ácido Glucárico , Humanos , Interleucina-6/biosíntesis , Ratones , Ratones Endogámicos SENCAR , Resveratrol , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/patología , Estilbenos/administración & dosificación , Acetato de Tetradecanoilforbol/toxicidad , Triterpenos/administración & dosificación , Ácido Ursólico
6.
Oncol Rep ; 26(3): 551-6, 2011 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-21687956

RESUMEN

Carcinogen-mediated labilization of lysosomal enzymes such as ß-glucuronidase (ßG) is often associated with the general process of inflammation. Therefore, the primary goal of this study was to demonstrate that exposing the skin of SENCAR mice to the natural ßG inhibitor D-glucaro-1,4-lactone (1,4-GL) and its precursor D-glucuronic acid-γ-lactone (GUL), prior to and during 7,12-dimethylbenz[α]anthracene (DMBA) treatment inhibits not only epidermal hyperplasia but also inflammation in the mouse skin complete carcinogenesis model, i.e., the 4-week inflammatory-hyperplasia assay. Topical administration of 1,4-GL or GUL prior to repetitive, high-dose DMBA treatment markedly and in a dose-related manner inhibited DMBA-induced epidermal hyperplasia (i.e., up to 57%). DMBA-mediated Ha-ras mutations in codon 61 were reduced by up to 78% by 1,4-GL. DMBA-induced inflammation, as measured by dermal leukocyte counts and immunologically, was inhibited by up to 37% by topical 1,4-GL but not by GUL. The inhibition of cellular proliferation and inflammation coincided with the inhibition of ßG expression. Thus, the present study suggests that in the DMBA-induced complete skin carcinogenesis model, 1,4-GL when applied topically had both anti-proliferative properties as well as anti-inflammatory properties, whereas GUL had only anti-proliferative when applied topically. However, the number of inflammatory cells in the dermal portion of the skin of mice was significantly reduced by dietary treatment of GUL, whereas both topical and dietary treatments with 1,4-GL were very effective.


Asunto(s)
Anticarcinógenos/farmacología , Ácido Glucárico/análogos & derivados , Glucuronatos/farmacología , Glucuronidasa/antagonistas & inhibidores , Proteínas HSP90 de Choque Térmico/metabolismo , Interleucina-1alfa/metabolismo , Neoplasias/patología , Piel/metabolismo , 8-Hidroxi-2'-Desoxicoguanosina , 9,10-Dimetil-1,2-benzantraceno , Administración Oral , Administración Tópica , Animales , Biomarcadores/metabolismo , Carcinógenos , Desoxiguanosina/análogos & derivados , Desoxiguanosina/metabolismo , Dermatitis por Contacto/etiología , Dermatitis por Contacto/metabolismo , Dermatitis por Contacto/patología , Femenino , Ácido Glucárico/administración & dosificación , Ácido Glucárico/farmacología , Glucuronatos/administración & dosificación , Glucuronidasa/metabolismo , Hiperplasia/inducido químicamente , Mediadores de Inflamación/metabolismo , Recuento de Leucocitos , Ratones , Ratones Endogámicos SENCAR , Neoplasias/etiología , Neoplasias/prevención & control , Piel/efectos de los fármacos , Piel/patología
7.
Oncol Lett ; 2(1): 145-154, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22870144

RESUMEN

Previous studies showed that dietary calcium D-glucarate (CG) inhibited benzo[a]pyrene (B[a]P)-induced A/J mouse lung tumorigenesis, suppressing cell proliferation and chronic inflammation and inducing apoptosis during late post-initiation stages. The present study aimed to investigate changes in the homeostasis of cytokines in blood serum, as well as alterations in biomarkers of inflammation and apoptosis in lung tissue caused by dietary CG during early post-initiation stages of B[a]P-induced lung tumorigenesis. Two doses of 3 mg of B[a]P were given intragastrically to A/J mice 2 weeks apart. CG administration in the AIN-93G diet (2 and 4%, w/w) commenced at 2 weeks following the second dose of B[a]P. The levels of interleukin (IL)-6, IL-10 and tumor necrosis factor α (TNFα) in blood serum were investigated by FCAP array analysis. Two weeks after the second dose of B[a]P, approximately 8- and 28-fold increases of TNFα and IL-6, respectively, occurred in the blood serum and an approximately 16% decrease of IL-10 levels compared to the untreated control group was noted. At 4 weeks after the second dose of B[a]P and after 2 weeks of CG administration in the diet, the 2 and 4% CG diets significantly reduced the levels of IL-6 and TNFα (by 70 and 33%, respectively). In a dose-related manner, the diets also increased the level of anti-inflammatory cytokine IL-10 compared to the B[a]P group. At 6 weeks after the second dose of B[a]P, the cytokine levels in the serum continued to show a decrease in the CG-treated groups. These events are accompanied by an increased level of cleaved caspase-9 product with a molecular weight of 37 kDa. In conclusion, dietary D-glucarate decreases the level of proinflammatory cytokines, increases the level of the anti-inflammatory cytokine IL-10 during early post-initiation stages of B[a]P-induced lung tumorigenesis in A/J mice and affects apoptotic induction.

8.
Cancer Prev Res (Phila) ; 3(2): 170-8, 2010 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-20103723

RESUMEN

The purpose of our study was to determine the inhibitory effect of combined phytochemicals on chemically induced murine skin tumorigenesis. Our hypothesis was that concurrent topical and dietary treatment with selected compounds would lead to more efficient prevention of skin cancer. We tested ellagic acid and calcium D-glucarate as components of diets, while resveratrol was applied topically; grape seed extract was applied topically or in the diet. The 4-week inflammatory-hyperplasia assay based on the 7,12-dimethylbenz[a]anthracene (DMBA)-induced skin carcinogenesis model in SENCAR mice was used. We have found that all the selected combinations caused a marked decrease of epidermal thickness compared with the DMBA-treated group and also with groups treated with a single compound and DMBA. All combinations of resveratrol with other compounds showed a synergistic effect on hyperplasia and Ha-ras mutations. Skin tissue of mice receiving the combinations showed decreased cell proliferation and Bcl2 expression; decreased p21, a regulator of cell cycle; and decreased marker of inflammation cyclooxygenase-2. All the selected combinations diminished the DMBA-induced mRNA expression of the CYP1B1 level, and also caused a marked decrease of proto-oncogenes c-jun and c-fos, components of transcription factor activator protein. In conclusion, all combinations showed either additive or synergistic effects and their joint actions allowed for decreasing the doses of the compounds. Especially, resveratrol combinations with ellagic acid, grape seed extract, and other phytochemicals are very potent inhibitors of skin tumorgenesis, based on the suppression of epidermal hyperplasia as well as on the modulation of intermediate biomarkers of cell proliferation, cell survival, inflammation, oncogene mutation, and apoptosis.


Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Protocolos de Quimioterapia Combinada Antineoplásica/farmacología , Fitoterapia/métodos , Neoplasias Cutáneas/prevención & control , Administración Tópica , Animales , Anticarcinógenos/farmacología , Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Quimioprevención/métodos , Dieta , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Ácido Elágico/administración & dosificación , Femenino , Genes ras/efectos de los fármacos , Ácido Glucárico/administración & dosificación , Extracto de Semillas de Uva/administración & dosificación , Ratones , Ratones Endogámicos SENCAR , Mutación , Resveratrol , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Estilbenos/administración & dosificación
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA